Consensus on mild asthma management : results of a modified Delphi study
Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Garcia, Gabriel (Hospital Rodolfo Rossi)
Gemicioglu, Bilun (Istanbul University-Cerrahpasa)
Van, Giap Vu (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias)
Larenas-Linnemann, Désirée (Clinical Foundation and Hospital)
Neffen, Hugo (Centro de Alergia e Inmunología y Enfermedades Respiratorias)
Poachanukoon, Orapan (Thammasat University Hospital)
Sagara, Hironori (Showa University School of Medicine)
Berend, Norbert (Respiratory Franchise)
Pizzichini, Emilio (Respiratory Franchise)
Irusen, Elvis (GlaxoSmithKline Biologicals)
Aggarwal, Bhumika (European Respiratory Society (ERS))
Eken, Volkan (Laboratorios Almirall, S.A.)
Levy, Gur (GlaxoSmithKline)
Universitat Autònoma de Barcelona

Date:	2022
Description:	13 pàg.
Abstract:	OBJECTIVE: In order to understand the role of regular controller inhaled corticosteroids (ICS) versus as-needed ICS-formoterol in managing mild asthma, we performed a modified Delphi procedure. METHODS: Opinions from 16 respiratory experts to three surveys and during a virtual scientific workshop helped to develop final consensus statements (pre-defined as 70% agreement). RESULTS: Thirteen participants completed all rounds (response rate 81%). At the end of the procedure, there was final consensus on: regular daily ICS being the recommended treatment approach in mild persistent asthma, with better symptom control and robust long-term clinical data compared with as-needed ICS-formoterol (85%); to avoid noncompliance, frequently seen in mild asthma patients, regular ICS dosing should be accompanied by ongoing education on treatment adherence (100%); treatment aims should be targeting asthma control (92%) and reduction of exacerbation risk (85%). No consensus was reached on whether GINA or national guidelines most influence prescribing decisions. CONCLUSIONS: It is important to encourage patients to be adherent and to target both asthma control and exacerbation risk reduction. There is robust clinical evidence to support proactive regular dosing with ICS controller therapy plus as-needed short-acting beta-agonists for the management of patients with mild asthma.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Delphi procedure ; ICS ; ICS-formoterol ; Inhaled corticosteroids ; Mild asthma
Published in:	Journal of Asthma, 2022, p. 1-13, ISSN 1532-4303

DOI: 10.1080/02770903.2022.2034850
PMID: 35099342

14 p, 2.5 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles